E
DFTX

Ergoteles’s Definium Therapeutics DFTX Stock Holding History

Ergoteles’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-72,507
Closed -$696K – 1818
2022
Q2 		$696K Buy
+72,507
New +$917K 0.02% 696
2022
Q1 		– Sell
-6,589
Closed -$136K – 1478
2021
Q4 		$136K Buy
6,589
+3,382
+105% +$108K 0.01% 1109
2021
Q3 		$112K Buy
+3,207
New +$139K ﹤0.01% 1084

Other funds holding DFTX

DCI
Data Collective IV Palo Alto, California $78.6M AUM 55.41% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $4.12B AUM 32.66% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Ergoteles's DFTX Position: Q3 2022 in Review

Ergoteles sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 72,507 shares — an estimated $696K sold.

Ergoteles first reported a position in DFTX in Q3 2021 and held it in 3 quarters. The position peaked at $696K in Q2 2022. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • Ergoteles reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 72,507 Definium Therapeutics shares in Q3 2022, an estimated $696K.
  • Ergoteles first reported a position in Definium Therapeutics in Q3 2021 and held it in 3 quarters.
  • Ergoteles's Definium Therapeutics position peaked at $696K in Q2 2022.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.